Apogee Therapeutics has initiated dosing of initial volunteers in a Phase 1 study of their new extended-duration IL-4Rα antibody, APG808, aimed at managing Chronic Obstructive Pulmonary Disease (COPD) and various inflammatory conditions.

Valsartan, a diminutive molecular compound, falls within the pharmacological group of angiotensin receptor blockers (ARBs).

Regeneron Pharmaceuticals, Inc. has declared the receipt of Complete Response Letters from the U.S. Food and Drug Administration concerning their submitted Biologics License Application for the drug odronextamab.

Preclinical research refers to the scientific studies conducted on potential drugs or medical devices before they are tested in humans.

Rhythm Pharma Initiates First Human Dosing in Early-Stage Study of RM-718, a Once-Weekly Compound Targeting MC4R Receptors.

Terbinafine, a small but powerful drug, works by blocking SQLE, a key enzyme in making ergosterol, which is essential for fungal cell membranes.

US FDA grants Bio-Thera Solutions approval to start Phase II trial of BAT8006, a novel ADC aimed at Folate Receptor alpha.

Active Pharmaceutical Ingredient (API) refers to the main substance in a drug that provides the therapeutic effect.

AbbVie Plans to Take Over Landos Biopharma, Enhancing Its Collection of Treatments for Inflammation and Autoimmunity.

Nystatin, a minuscule molecule drug with a penchant for functioning as an ergosterol binder, engages in targeting fungal cells, blocking their growth and replication.

Ferrer and Verge Genomics have entered into a collaboration to jointly advance the experimental treatment for ALS, designated as VRG50635, into clinical trials.

Phagocytosis is an essential immune response where phagocytes consume foreign particles, dead cells, and pathogens like bacteria and viruses.